RNFT1 Inhibitors

RNFT1 inhibitors includes kinase inhibitors such as Staurosporine, which can influence the phosphorylation state of RNFT1, thereby modulating its functional activity and protein stability. LY294002 and Wortmannin act upstream within the PI3K/Akt signaling pathway, where their inhibition can indirectly affect the regulation of RNFT1. The MEK inhibitor PD98059 and p38 MAPK inhibitor SB203580 can adjust RNFT1 activity by altering the MAPK/ERK and stress response pathways. U73122 disrupts phospholipase C activity, impacting second messenger systems that can regulate RNFT1, while the calcium chelator BAPTA can modulate calcium-dependent processes linked to RNFT1 function.

SP600125, targeting JNK, can influence RNFT1 through stress-activated protein kinase pathways. MG132 can alter RNFT1 activity by preventing the degradation of regulatory proteins that control its function. ZM-447439, an Aurora kinase inhibitor, can indirectly affect RNFT1 during cell cycle progression. Rapamycin, an mTOR inhibitor, can alter RNFT1 regulation through the mTORC1 signaling pathway, and NF449, a G-protein antagonist, can disrupt G-protein coupled signaling pathways that involve RNFT1.